Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sunil R. Hingorani
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Halozyme
Payment for services (e.g., consulting fees, honoraria, paid authorship)
This proposal applies rigorously defined genetically engineered mouse models of pancreas cancer to translate therapeutic regimens that target both the stromal and epithelial compartments of the disease. Dr. Hingorani’s previous work defined a strategy to administering a long-acting, PEGylated formulation of hyaluronidase (PEGPH20) in order to degrade intratumoral hyaluronan (HA), release the complexed water, reduce interstitial fluid pressure and allow collapsed vessels to re-expand and re-perfuse to increase penetration of subsequently administered agents. This approach is currently being tested in Phase 3 clinical trials. This current R01-funded research pursues a series of complementary investigations to rigorously investigate the role of hyaluronan (HA) in promoting the pathogenesis and aggressive biology of PDA (pancreatic ductal adenocarcinoma). The aims proposed in this 5-year project will involve administration of PEGPH20 in a variety of genetically engineered mouse models of pancreas cancer, using a variety of therapeutic strategies including PEGPH20 monotherapy as well as PEGH20 in combination with other therapeutic agents and approaches. PEGPH20 is provided free of charge from Halozyme Therapeutics.
Overcoming stromal barriers to therapeutics in pancreas cancer
PROJECT NARRATIVE Pancreas cancer kills every patient it afflicts and is now the fourth leading cause of cancer-related deaths in this country with a rising incidence and unabated mortality. We have developed genetically engineered animal models of pancreas cancer that have exposed unique points of vulnerability for the development of new treatments. We propose a systematic program of investigation to target distinct components of the stromal reaction in pancreas cancer as the basis for new treatment strategies against this highly resistant disease.
Filed on August 22, 2016.
Tell us what you know about Sunil R. Hingorani's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Sunil R. Hingorani filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sunil Hingorani | Fred Hutchinson Cancer Research Center | Conflict of Interest | Halozyme | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.